

Merck invests €25 M for accelerating European expansion plans

18 March 2021 | News

The investment in Molsheim will add more than 350 new jobs in total

Merck, a leading science and technology company, will add a single-use assembly production unit at its Life Science Center in Molsheim, France. With the € 25 million investment, the company is accelerating its European expansion plans for this key technology, which is used for the production of Covid-19 vaccines and other lifesaving therapies.

Molsheim will be the first site in Europe where Merck manufactures the product. Further production sites are located in Danvers, Massachusetts, USA, and Wuxi, China.

The investment in Molsheim will add more than 350 new jobs in total along with 1,700 square meters of ISO7 or ISO5 cleanrooms, using modular building design and existing infrastructure to allow future expansions without any disruptions. The new unit will produce Mobius® single-use assemblies, a key offering that is part of Merck's Mobius® MyWay program. It is planned to be operational by the end of 2021.

With more than 1,700 employees of 32 different nationalities, and producing more than 10,000 products, the Molsheim hub is Merck's third largest site globally. It supplies the world market, exporting more than 85 percent of its production. It hosts three production units dedicated to the manufacture and assembly of products and solutions for pharmaceutical manufacturing processes and applied solutions products for analysis in clinical and industrial environments and water purification systems.